This is the authors' abstract. We don't add key points for this paper.
Cefamandole is reported to have in-vitro activity against Staphylococcus aureus comparable to that of cephalothin and cefazolin (Ernst et al., 1976) and to possess an expanded spectrum to include activity for Haemophilus influenzae and the Enterobacteriaceae (Eng, 1984). Hence, cefamandole has been considered to be potentially valuable as initial therapy for those patients with suspected sepsis involving staphylococci, H. influenzae or enteric Gram-negative bacilli. Because of these in-vitro data, cefamandole was evaluated during 1978 to 1979 for its efficacy in the therapy of patients with bacteraemia or endocarditis due to Staph. aureus. Six cases of Staph. aureus bacteraemia were treated with cefamandole. Not summarized are two cases in which the patients were initially given cefamandole and one developed an allergic skin erruption and the other developed a positive Coombs' reaction and therapy had to be changed. The following four cases are failures of cefamandole in the treatment of serious staphylococcal infections.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Eng et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: